While combined mTOR, IGF1R, and MEK inhibition shows significant tumor regression in K-RasG12C–driven lung cancer mouse models, replacing the MEK inhibitor with a K-RasG12C inhibitor in combination demonstrates greater efficacy, specificity, and tolerability (Molina-Arcas et al., 2019). Here, MTOR is linked to neoplasm.